Baxter has completed its acquisition of Sanofi’s Seprafilm adhesion barrier, acquiring the device and related assets for $350 million.
The gel-like surgical implant prevents the formation of scar tissue between organs and tissues. It is used to significantly reduce the severity and occurrence of adhesion following abdominopelvic surgery.
“Adhesions can be a source of major post-surgical complications and often require revision, or a second surgery to remove the adhesions,” Baxter said. “Adhesion prevention products…are important tools surgeons use to manage intraoperative bleeding and reduce adhesions.”